Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) (C-Term) Peptide
PARK2
Reactivité: Souris
Hôte: Synthetic
BP, WB
-
- Antigène Tous les produits Parkin (PARK2)
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
- Protein Region
- C-Term
- Origine
- Souris
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Séquence
- YTRYQQYGAE ECVLQMGGVL CPRPGCGAGL LPEQGQRKVT CEGGNGLGCG
- Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-Park2 Antibody(ARP43038_P050),. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Antigène
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
- Synonymes
- CG10523 Peptide, Dmel\\CG10523 Peptide, Dpark Peptide, SD01679 Peptide, dpk Peptide, AR-JP Peptide, LPRS2 Peptide, PDJ Peptide, PRKN Peptide, Park Peptide, Prkn Peptide, si:ch211-123f21.1 Peptide, zgc:112390 Peptide, pdr-1 Peptide, PARK2 Peptide, parkin Peptide, parkin RBR E3 ubiquitin protein ligase Peptide, Parkinson disease (autosomal recessive, juvenile) 2, parkin Peptide, park Peptide, PRKN Peptide, Prkn Peptide, prkn Peptide, CpipJ_CPIJ014867 Peptide, Park2 Peptide
- Sujet
-
Park2 functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5 and AIMP2. Park2 may play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Park2 limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of AR-JP. Park2 may protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. Park2 may play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Park2 regulates cyclin E during neuronal apoptosis. Park2 may represent a tumor suppressor gene. Park2 promotes the autophagic degradation of dysfunctional depolarized mitochondria.
Alias Symbols: MGC130518, PRKN
Protein Size: 464 - Poids moléculaire
- 51 kDa
- ID gène
- 50873
- NCBI Accession
- NM_016694, NP_057903
- UniProt
- Q9WVS6
-
Vous êtes ici:
